Please login to the form below
JAK inhibitors
This page shows the latest JAK inhibitors news and features for those working in and with pharma, biotech and healthcare.
Researchers use AI to identify drugs that could be repurposed for Alzheimer’s
Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing. ... JAK inhibitors are commonly used to treat conditions such as rheumatoid arthritis and blood cancers, and block the action of JAK proteins, which play a role in
Latest news
-
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19
A study of Eli Lilly’s JAK inhibitor Olumiant in combination with Gilead’s antiviral med remdesivir met its primary endpoint in patients hospitalised with COVID-19. ... therapies. Researchers have theorised that anti-inflammatory drugs, such as IL-6
-
New study identifies drugs that are safe to use in COVID-19 treatment
The study also found that other types of drugs – such as TNF blockers and JAK inhibitors – are also safe to use in the treatment of COVID-19.
-
Incyte’s JAK inhibitor cream clears second eczema trial
The reformulation could open up a new and very large treatment category for the drug, as well as new territory for the JAK inhibitor class. ... A potentially big advantage for Incyte with its topical formulation is lower systemic exposure to the active
-
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
This includes a new class of JAK inhibitors, such as AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib). ... ICER’s conclusion that Rinvoq, in particular, only had a ‘marginal’ benefit over
-
AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER
In the latest update of its evidence report issued yesterday, the Institute for Clinical and Economic Review (ICER) concluded that AbbVie’s JAK inhibitor Rinvoq (upadacitinib) provided a ‘marginal’ benefit over ... The US-based cost-effectiveness
More from news
Approximately 1 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
JAK inhibitors such as Xeljanz and Rinvoq. ... It faces competition from entrenched generic metformin and sulphonylureas, as well as from more novel drug classes, particularly SGLT-2, inhibitors, DDP4 inhibitors and injectable GLP-1 agonists.
-
20 for 2020 – Five pharma leaders to watch in 2020
pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia. ... and filgotinib’s anticipated launch this year meets
-
Pharma deals during December 2012
In return for this hefty premium, Gilead acquires a company with an annual cash burn of $30m developing orally active JAK 1 / JAK 2 kinase inhibitors and with a lead product, ... Company acquisition. JAK kinase inhibitors development company. 510. Sutro /
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Today, some of the most innovative therapies in development are Janus kinase (JAK) inhibitors, and the latest ‘game changer’ Tyrosine kinase 2 (TYK2) inhibitors. ... The healthcare press has described TYK2 inhibitors as having the potential
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living With data, our syndicated patient report series shows that JAK inhibitors have already made a strong impression ... Topics covered in the webcast include:. The
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
Topics to be covered include:. The European RA market. Current status and market situation of JAK inhibitors (key EU5 countries). ... Profile of physicians prescribing JAKS. Country differences. The future of new classes of JAK inhibitors.
-
The Biosimilar Challenge
Source: Adelphi Online Survey with N=55 Trust Pharmacists/CCG Commissioners/CCG HMM/HMOs. Theoretically cost-savings should be freeing up funds for new branded therapies such as JAK Inhibitors but
-
Brand leaders in RA will lose market share, predict rheumatologists
JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Biogen and Happify Health team up to create digital platform for MS patients
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Moderna to launch Innovation and Technology Center in the UK
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- How pharma found its voice – health communications for a brave new world
- The importance of beliefs in creative health engagement
- In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
- The Evolving Role of the Sales Rep
- Measure your omnichannel maturity with our new tool
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Almirall shares positive topline results from atopic dermatitis trials
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
PMHub
Research Partnership
Research Partnership has joined Ashfield Advisory, the consulting division of healthcare marketing services company, Ashfield. As the market insights specialist...
Latest intelligence
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
- Report: Omnichannel advice for the life science industry
- In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
